Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Insight Molecular Diagnostics (IMDX) Other Gross PP&E Adjustments (2016 - 2026)

Insight Molecular Diagnostics' Other Gross PP&E Adjustments history spans 7 years, with the latest figure at -$14.4 million for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments fell 38.64% to -$14.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$14.4 million, a 38.64% decrease, with the full-year FY2025 number at -$14.4 million, down 38.64% from a year prior.
  • Other Gross PP&E Adjustments hit -$14.4 million in Q4 2025 for Insight Molecular Diagnostics, down from -$12.9 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for IMDX hit a ceiling of $4.7 million in Q2 2021 and a floor of -$15.7 million in Q3 2022.
  • Historically, Other Gross PP&E Adjustments has averaged -$8.4 million across 5 years, with a median of -$10.8 million in 2023.
  • Biggest five-year swings in Other Gross PP&E Adjustments: skyrocketed 441.68% in 2021 and later tumbled 881.41% in 2023.
  • Tracing IMDX's Other Gross PP&E Adjustments over 5 years: stood at -$4.5 million in 2021, then tumbled by 203.02% to -$13.7 million in 2022, then skyrocketed by 32.45% to -$9.3 million in 2023, then decreased by 11.94% to -$10.4 million in 2024, then plummeted by 38.64% to -$14.4 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for IMDX at -$14.4 million in Q4 2025, -$12.9 million in Q3 2025, and -$12.6 million in Q2 2025.